Abstract
Von Hippel-Lindau disease is a dominantly inherited familiar cancer disease characterized by the development of a variety of neoplasms, either benign or malignant, as well as cysts in different organs of the body. The disease depends on the inactivation of the VHL gene in the short arm of chromosome 3 (3p25–26.6) with high penetrance and variable expression (Maddock et al. 1996; Neumann et al. 1992; Seizinger et al. 1991). The protein encoded by this gene is unique and inhibits transcription elongation resulting in unregulated growth of vascular tumors in multiple tissues. The cardinal tumors of the disease for the neurosurgeon – hemangioblastomas (HBs) and retinoblastomas – are due to the abnormal focal proliferation of newly formed vessels which may cause life-threatening complications in spite of their benign nature because of their common location in the brain and spinal cord. When involving the retina, these tumors may impair the visual function leading to visual loss when poorly managed. The cysts, typical of the disease, commonly involve the kidneys, pancreas, and genital tracts. Often these lesions are detected in asymptomatic subjects and require the differential diagnosis with other benign lesions that do not bear a similar increased risk to develop clear cell renal carcinomas or pancreatic neuroendocrine tumors.
Similar content being viewed by others
References
Ammerman JM, Lonser RR, Dambrosia J et al (2006) Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg 105:248–255. doi:10.3171/jns.2006.105.2.248
Baghai M, Thompson GB, Young WF et al (2002) Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg 137:682–688; discussion 688–689
Ben-Skowronek I, Kozaczuk S (2015) Von Hippel-Lindau disease. Horm Res Pædiatrics 84:145–152. doi:10.1159/000431323
Bissada NK, Safwat AS, Seyam RM et al (2008) Pheochromocytoma in children and adolescents: a clinical spectrum. J Pediatr Surg 43:540–543. doi:10.1016/j.jpedsurg.2007.10.038
Butman JA, Linehan WM, Lonser RR (2008) Neurologic manifestations of von Hippel-Lindau disease. JAMA 300:1334–1342. doi:10.1001/jama.300.11.1334
Carlson ML, Thom JJ, Driscoll CL et al (2013) Management of primary and recurrent endolymphatic sac tumors. Otol Neurotol 34:939–943. doi:10.1097/MAO.0b013e31828680da
Chen F, Kishida T, Yao M et al (1995) Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75. doi:10.1002/humu.1380050109
Choo D, Shotland L, Mastroianni M et al (2004) Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg 100:480–487. doi:10.3171/jns.2004.100.3.0480
Choyke PL, Glenn GM, Walther MM et al (1995) von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 194:629–642. doi:10.1148/radiology.194.3.7862955
Crossey PA, Richards FM, Foster K et al (1994) Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3:1303–1308
Duan DR, Pause A, Burgess WH et al (1995) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269:1402–1406. doi:10.1126/science.7660122
Florczak E, Prejbisz A, Szwench-Pietrasz E et al (2013) Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens 27:678–685. doi:10.1038/jhh.2013.32
Frantzen C, Klasson TD, Links TP, Giles RH (1993) Von Hippel-Lindau Syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2017
Friedrich CA (1999) Von Hippel-Lindau disease: a pleomorphic condition. Cancer 86:2478–2482
Friedrich C a (2001) Genotype-phenotype correlation in von Hippel-Lindau disease. Hum Mol Genet 10:763–767. doi:10.1093/hmg/10.7.763
Hes F, Zewald R, Peeters T et al (2000) Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum Genet 106:425–431. doi:10.1007/s004390000265
Hes FJ, Lips CJ, van der Luijt RB (2001) Molecular genetic aspects of Von Hippel-Lindau (VHL) disease and criteria for DNA analysis in subjects at risk. Neth J Med 59:235–243
Hough DM, Stephens DH, Johnson CD, Binkovitz LA (1994) Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol 162:1091–1094. doi:10.2214/ajr.162.5.8165988
Ikeda Y, Takami H, Niimi M et al (2001) Laparoscopic partial or cortical-sparing adrenalectomy by dividing the adrenal central vein. Surg Endosc 15:747–750. doi:10.1007/s004640080112
Jagannathan JJN (2008) Surgical management of cerebellar hemangioblastomas in patients with von Hippel–Lindau disease. J Neurosurg 108:210–222. doi:10.3171/JNS/2008/108/2/0210
Kaelin WG (2002) Molecular basis of the VHL hereditary cancer disease. Nat Rev Cancer 2:673–682. doi:10.1038/nrc885
Kanno H, Yamamoto I, Nishikawa R et al (2009) Spinal cord hemangioblastomas in von Hippel-Lindau disease. Spinal Cord 47:447–452. doi:10.1038/sc.2008.151
Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG (1995) Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269:1444–1446. doi:10.1126/science.7660130
Kim H, Yi JH, Kwon HJ et al (2014) Therapeutic outcomes of retinal hemangioblastomas. Retina 34:2479–2486. doi:10.1097/IAE.0000000000000254
Knudson AG (1986) Genetics of human cancer. Annu Rev Genet 20:231–251. doi:10.1146/annurev.ge.20.120186.001311
Kreusel K-M, Bechrakis NE, Krause L et al (2006) Retinal angiomatosis in von Hippel-Lindau disease: a longitudinal ophthalmologic study. Ophthalmology 113:1418–1424. doi:10.1016/j.ophtha.2006.02.059
Latif F, Tory K, Gnarra J et al (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320. doi:10.1002/anie.201102909
Leung RS, Biswas SV, Duncan M, Rankin S (2008) Imaging features of von Hippel-Lindau disease. Radiographics 28:65–79; quiz 323. doi:10.1148/rg.281075052
Levine E, Lee KR, Weigel JW, Farber B (1979) Computed tomography in the diagnosis of renal carcinoma complicating Hippel-Lindau disease. Radiology 130:703–706. doi:10.1148/130.3.703
Libutti SK, Choyke PL, Bartlett DL et al (1998) Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery 124:1153–1159
Lonser RR (2014) Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg 120:1055–1062
Lonser RR, Glenn GM, Walther M et al (2003a) von Hippel-Lindau disease. Lancet 361:2059–2067
Lonser RR, Weil RJ, Wanebo JE et al (2003b) Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 98:106–116. doi:10.3171/jns.2003.98.1.0106
Maddock IR, Moran a, Maher ER et al (1996) A genetic register for von Hippel-Lindau disease. J Med Genet 33:120–127. doi:10.1136/jmg.33.2.120
Maher ER, Yates JR, Harries R et al (1990) Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77:1151–1163
Manski TJ, Heffner DK, Glenn GM et al (1997) Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 277:1461–1466
Maxwell PH, Wiesener MS, Chang GW et al (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275. doi:10.1038/20459
Mehta GU (2010) Functional outcome after resection of spinal cord hemangioblastomas associated with von Hippel-Lindau disease. J Neurosurg 12:233–242. doi:10.3171/2009.10.SPINE09592
Neumann HP, Dinkel E, Brambs H et al (1991) Pancreatic lesions in the von Hippel-Lindau disease. Gastroenterology 101:465–471
Neumann HP, Eggert HR, Scheremet R et al (1992) Central nervous system lesions in von Hippel-Lindau disease. J Neurol Neurosurg Psychiatry 55:898–901
Osborn A et al (2004) Diagnostic imaging. Brain. In: First. AMYRSYS, pp 84–88
Page KA, Wayson K, Steinberg GK, Adler JR (1993) Stereotaxic radiosurgical ablation: an alternative treatment for recurrent and multifocal hemangioblastomas. A report of four cases. Surg Neurol 40:424–428
Pause A, Lee S, Worrell RA et al (1997) The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 94:2156–2161
Pavlovich CP, Linehan WM, Walther MM (2001) Partial adrenalectomy in patients with multiple adrenal tumors. Curr Urol Rep 2:19–23
Richard S, Campello C, Taillandier L et al (1998) Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J Intern Med 243:547–553
Seizinger BR, Smith DI, Filling-Katz MR et al (1991) Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease. Proc Natl Acad Sci U S A 88:2864–2868
Sgambati MT, Stolle C, Choyke PL et al (2000) Mosaicism in von Hippel – Lindau disease: lessons from Kindreds with germline mutations identified in offspring with Mosaic parents. Am J Hum Genet 66:84–91. doi:10.1086/302726
Shanbhogue KP, Hoch M, Fatterpaker G, Chandarana H (2016) von Hippel-Lindau disease. Radiol Clin N Am 54:409–422. doi:10.1016/j.rcl.2015.12.004
Stolle C, Glenn G, Zbar B et al (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12:417–423. doi:10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K
Takai K, Taniguchi M, Takahashi H et al (2010) Comparative analysis of spinal hemangioblastomas in sporadic disease and Von Hippel-Lindau disease. Neurol Med Chir (Tokyo) 50:560–567
Taouli B, Ghouadni M, Corréas J-M et al (2003) Spectrum of abdominal imaging findings in von Hippel-Lindau disease. AJR Am J Roentgenol 181:1049–1054. doi:10.2214/ajr.181.4.1811049
Van Velthoven V, Reinacher PC, Klisch J et al (2003) Treatment of intramedullary hemangioblastomas, with special attention to von Hippel-Lindau disease. Neurosurgery 53:1306–1313; discussion 1313–1314
Vougioukas VI, Gläsker S, Hubbe U et al (2006) Surgical treatment of hemangioblastomas of the central nervous system in pediatric patients. Childs Nerv Syst 22:1149–1153. doi:10.1007/s00381-005-0018-y
Walther MM, Reiter R, Keiser HR et al (1999) Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162:659–664
Wanebo JE, Lonser RR, Glenn GM, Oldfield EH (2003) The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 98:82–94. doi:10.3171/jns.2003.98.1.0082
Winn HR (2011) Hemangioblastomas. In: Youmans and Winn neurological surgery, 6th edn. Elsevier, Philadelphia, pp 1392–1395
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this entry
Cite this entry
Giordano, M., Arraez, C., Di Rocco, C. (2017). Von Hippel-Lindau Disease. In: Di Rocco, C., Pang, D., Rutka, J. (eds) Textbook of Pediatric Neurosurgery. Springer, Cham. https://doi.org/10.1007/978-3-319-31512-6_46-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-31512-6_46-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-31512-6
Online ISBN: 978-3-319-31512-6
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences